click enter text
initi peer perform pt visibl
invest view challeng driven chang gener
purchas polici food lab network china expect agil organ
growth recov mid-singl digit late
compound top-quartil increment margin slower growth
china/appli market last two quarter lower bar stock
ytd vs tool median polici chang china
ultim resolv allow growth recov assign spend rate
outlin plan agil substanti capit
deploy option tool bia posit agil growth
uniqu sensit global trade keep risk estim elev
diverg vs consensu macro work flag agil
sensit compani tool global trade rais question around view
recent slow tie china domest polici see strong
relationship agil organ growth capit good trade data
pressur indic risk near term forecast
organ growth estim low end guidanc resolut
trade disput expect growth reacceler within month support
meaning upsid consensu organ expect implicitli model
sharp organ deceler consid high visibl
increment revenu nasd capac expans
valuat framework pt deriv forecast
target yield yield target tool averag given
neg signal macro index spite expect in-lin
growth detail valuat methodolog industri note
forecast assum increment free cash deploy return
trade fundament data
upsid target
price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
investor concern pressur multipl question linger
present global
great asset uncertain time agil
arguabl truli industri compani
coverag go transit china
central/feder regional/priv lab
sensit need industri
uncertainti moder macro trend
critic agil rel coverag like
franchis sell truli industri custom
typic life scienc product line
deferr chemistri purchas higher-spec
instrument use discoveri given
dynam view agil
growth asset above-p margin
expans potenti time rate agil
peer perform ahead clariti global trade
dynam signal stabilization/revers
broader macro indic set
agilent-custom macro composit stock
five-year low rel multipl believ
market clearli board much think
bull case clearer
quarter beyond macro uncertainti
struggl present potenti
stock particularli macro fear elev
expect china/gener dynam resolv year-
end see potenti trade resolut
develop would support case
upsid number stock depress
multipl agil strongest balanc sheet
tool net cash balanc vs group median
net debt ev/ebitda cap deploy
model assum return drive
invest incom worth ep accret
exhibit yield elev rel growth forecast
exhibit p-e reflect discount peer group
page
yieldfcf compound-annual-growth-rate price-to-earnings premium tool median median median
macro indic highlight capit trade exposur
reason cautiou agil
macro backdrop asid weve seen
commentari agil
slow april quarter concentr
food segment pharma china
polici known concern
concern us slow
busi actual broad-bas
consid compar map
exhibit appendix report
academ govern pick quarter
area visibl weaker quarter quarter
actual environment food
pharma visibl macro index work seen
asid see risk industri appli
flag pharma steadi fact
basi agil pharma busi
steadi account year-ago sell
review seri candid variabl
tight relationship year year organ
chang found pharma industri
segment agil strong seri
candid correl select index
constitu reflect mix region
sourc fund index incorpor us
export product analyt instrument cost
expect healthcar manufactur
trend europ
given signal macro work
neg trend global trade/pmis/chem
industri commentari see expect
near term recoveri prematur would like
see posit turn macro indic
resolut china becom
page
chang org qtli yoy chang mthli quarteryoy chang monthli vs yoy chang qtrli org pharma aorg chang org qtli yoy chang mthli quarteryoy chang vs yoy chang org industri aorg chang org qtli yoy chang mthli quarteryoy chang vs yoy chang org appli aorg per average
happen china arguabl biggest sourc confus right impact china
program gener pharma market sens agil compani impact
capit purchas pressur gener market china acut surpris
move see global rippl effect broader gener market contact pharma space
surpris speed magnitud impact hardwar purchas consensu narr
china initi issu global impact logic outcom either fear broader
gener space china local player unload inventori region percept
agilent/wat equip own compani ultim liquid due program sell
hardwar second hand market regardless specif mechan program expect impact
program last multipl quarter reach china tier citi china food exposur
shift central region privat lab introduc increment uncertainti make food effect
cyclic privat lab mix includ industri custom sens china becom
industri agil long horizon china prioriti remain concentr build local capabl
pharma energi
upsid driver dgg dako expand
oligonucleotid manufactur agil
contract dako technolog primari
pathology/slid vendor sonic
healthcar contract could drive sampl volum
approach slide per year per slide
importantli agil million invest
expand potenti longer term
capac frederick oligonucleotid dna
fragment drug applic product site
drive increment revenu ramp
site present go fda
valid agil estim oligo market
grow least
page
categori build accel idiosyncrat revenu driver contribut growth bp lasergennucl acid solutionsdako
survey confirm execut commerci initi
market share trajectori like durabl like agil benefit combin larg servic
organ support heavier in-person rep presenc broader product set rel competitor
time agil scale invest softwar offer crosslab consum
platform varian acquisit brought agil servic busi drive higher servic attach
rate higher consum pull-through exist instal base largest industri expect
traction servic penetr pharma custom base servic mix drive organ growth
higher less cyclic profil analysi share trend acut focu intuvo
initi given multi-year sell cycl agil domin posit space make increment share
margin opportun moder balanc sheet upsid risk
margin outlook attract though less prior ramp agil agil agil organ margin
expans compress bp year bp spite organ growth
fastest sinc manag commentari note lever margin expans agil
call margin expans outset year spite bp pressur spend lasergen
colorado/oligonucleotid product capac expans initi guidanc impli organ bp discret
cost action like save agil per year tailwind fade newer program
drive annual save impli roughli bp organ margin expans top organ
growth leverag moder vs bp trajectori
capit deploy option upsid swing factorwhen emerg agil hire raha
eric gerber highlight compani focu capit deploy interest growth
area cell analysi bioproduct specialti diagnost sequenc cell analysi busi
agil challeng effort form funnel begin key target
acquir agil strongest balanc sheet group ex-ilmn could drive ep
accret model assum elev cash interest incom proxi accret capit
deploy path accret look longer howev agil continu focu bolt-on deal
page
anticip pharma market share chang previou month vs next month data anticip academ market share chang previou month vs next month data bp consum lcmsservicesoftw
medium term project attain driven margin capit deploy
exhibit agil medium term project vs wolf consensu forecast
note total life scienc defin sum academ
revenu total regul dx food env forens total
cyclic dx food env pertin industri
page
estimate consensuswolf estimate consensuswolf revenu op om om project per oper modelfi categori mixfood safetyenvironment forensicschemical/energyacadem governmentdiagnosticspharma life sciencetot regulatedtot cyclicalexposur tool sectorapkitmowattmotmobrkrbrkrbrkrmtdmtdmtdwatwatqgendhrqgenqgendhrdhrpkipkiaa
exhibit wolf vs consensu forecast agil organ
growth rel peer
note differ organ revenu growth wolf weight
averag tool coverag
note organ growth consensu estim consensu nomin growth
estim less wolf estim inorgan impact revenu fx sell
day
page
 revenu rel organ growth vs stack accel/decel organ growth momentum estimateswolfeconsensuscon wgtd diff con wgtd diff excl -brkr
exhibit agil mix pharma academ rel peer
exhibit agil mix pharma sale rel peer
page
organ mix recur revenuesacademicpharmasub-totaltot pharma salescro/cdmo salesr mfg small mol qa/qcsoftware/ servicessmal mol biotech/ larg wgtd exposur sub-categori
exhibit improv organ increment ebit margin
exhibit agil organ ebit margin expans consist
note top bar repres report margin expans given year
exhibit ebit margin expans modestli ahead
exhibit project growth
note agil includ keysight bill fx ilab multiplicom
dilut pension chang bond yield includ charg
page
exhibit capit deploy project exhibit growth alloc
page
organ margin ex ex dilut margin increment non-gaap net per year plu major revenue-gener invest acapexdividend grow per year share repurchas minimum anti-dilut capit deploymentoper flow alloc work free
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
page
estimate ex calcul ex
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
note figur million unless state per-shar term data pend file
page
agil balanc l-t current long-term comp debt capit metricsday sale oustand day payabl outstand convers net
note figur million unless state per-shar term
page
agil incom continu work cash flow continu cash flowscapex pp acquisit cash cont op cash dc op invest financ cash flow stock compens issuanc stock facil proce facil outlow debt sale debt payment cash cont op cash dc op net financ fx impact oper net chang begin end metric free yield non- non-
